Education
About Us
Working with TipRanks
Follow Us
Antengene Corporation Limited (DE:722)
FRANKFURT:722
722 Stock Chart & Stats
€0.53
>-€0.01(-1.45%)
At close: 4:00 PM EST
€0.53
>-€0.01(-1.45%)
Day’s Range― - ―
52-Week Range€0.11 - €0.85
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€237.26M
Enterprise Value€1.31B
Total Cash (Recent Filing)€794.19M
Total Debt (Recent Filing)€234.85M
Price to Earnings (P/E)―
Beta0.25
Next Earnings
Mar 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding679,446,660
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.45
Price to Sales (P/S)4.12
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~50% revenue growth indicates durable commercial traction and/or milestone/licensing receipts. Over 2–6 months this supports runway, validates clinical progress to partners, and increases probability of securing further milestone or royalty-based income without relying solely on equity raises.
High Gross MarginA near-81% gross margin reflects favourable underlying economics from licensing, milestone and eventual product sales. This structural margin buffer can sustainably absorb elevated R&D and commercialization costs as products advance, improving long-term unit economics once revenues scale.
Low Leverage / Strong Equity RatioHigh equity funding and low debt provide financial flexibility to fund clinical development and absorb setbacks. Over the medium term this reduces refinancing risk, preserves strategic optionality for partnerships or acquisitions, and supports continued investment in the pipeline.
Bears Say
Severe Net LossesExtremely negative net margins signal that operating costs far outstrip revenues, creating structural cash burn. Without material margin improvement or sustained milestone inflows, the company will likely need external funding, diluting shareholders and constraining long-term R&D and commercialization plans.
Weak Cash GenerationRecurrent negative operating and free cash flows indicate inability to convert revenue into usable cash. This undermines self-funding for trials and launches, increasing dependence on partner payments or capital markets and raising execution risk for mid-term development milestones.
Erosion Of Equity BaseOngoing losses that reduce shareholder equity weaken the balance sheet buffer, limiting capacity to absorb adverse trial or regulatory outcomes. Over a 2–6 month horizon this constrains access to non-dilutive financing, may trigger tighter lending terms, and reduces strategic flexibility.
Antengene Corporation Limited News
722 FAQ
What was Antengene Corporation Limited’s price range in the past 12 months?
Antengene Corporation Limited lowest stock price was €0.11 and its highest was €0.85 in the past 12 months.
What is Antengene Corporation Limited’s market cap?
Antengene Corporation Limited’s market cap is €237.26M.
When is Antengene Corporation Limited’s upcoming earnings report date?
Antengene Corporation Limited’s upcoming earnings report date is Mar 20, 2026 which is in 32 days.
How were Antengene Corporation Limited’s earnings last quarter?
Antengene Corporation Limited released its earnings results on Aug 22, 2025. The company reported -€0.015 earnings per share for the quarter, beating the consensus estimate of -€0.027 by €0.012.
Is Antengene Corporation Limited overvalued?
According to Wall Street analysts Antengene Corporation Limited’s price is currently Overvalued.
Does Antengene Corporation Limited pay dividends?
Antengene Corporation Limited does not currently pay dividends.
What is Antengene Corporation Limited’s EPS estimate?
Antengene Corporation Limited’s EPS estimate is -0.03.
How many shares outstanding does Antengene Corporation Limited have?
Antengene Corporation Limited has 679,446,660 shares outstanding.
What happened to Antengene Corporation Limited’s price movement after its last earnings report?
Antengene Corporation Limited reported an EPS of -€0.015 in its last earnings report, beating expectations of -€0.027. Following the earnings report the stock price went down -3.597%.
Which hedge fund is a major shareholder of Antengene Corporation Limited?
Currently, no hedge funds are holding shares in DE:722
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Antengene Corporation Limited
Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. Its products in pre-clinical stage include ATG-037 (CD73 inhibitor) for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031 (CD24 antibody); ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 (LILRB antibody); and ATG-041, an Axl-Mer inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.
Technical Analysis
Ascletis Pharma, Inc.
―
TOT BIOPHARM International Co. Ltd.
―
Jiangsu Recbio Technology Co., Ltd. Class H
―
SinoMab Bioscience Ltd.
―
Immunotech Biopharm Ltd
―
Options Prices
Currently, No data available
---